IDH1 and central nervous system cancer: In gliomas, the identification of 2-hydroxyglutarate as an oncometabolite produced by mutant IDH1 not only provided a diagnostic marker but also led to the development of FDA-approved IDH-targeted therapies (Baek et al., 2024; Xu et al., 2019).